Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina
Overview
Authors
Affiliations
Background: Quadrivalent cell-based influenza vaccines (QIVc) avoid egg-adaptive mutations and can be more effective than traditional quadrivalent egg-based influenza vaccines (QIVe). This analysis compared the cost-effectiveness of QIVc and QIVe in Argentinian populations < 65 years old from the payer and societal perspectives. Methods: A static decision tree model compared the costs and health benefits of vaccination with QIVc vs. QIVe using a one-year time horizon. The relative vaccine effectiveness of QIVc vs. QIVe was assumed to be 8.1% for children and 11.4% for adults. An alternative high egg-adaptation scenario was also assessed. Model inputs were sourced from Argentina or the international literature. Deterministic and probabilistic sensitivity analyses were performed. Results: Compared to QIVe, QIVc would prevent 17,857 general practitioner visits, 2418 complications, 816 hospitalizations, and 12 deaths per year. From the payers’ perspective, the incremental cost-effectiveness ratio per quality-adjusted life years gained was USD12,214 in the base case and USD2311 in the high egg-adaptation scenario. QIVc was cost-saving from the societal perspective in both scenarios. Conclusions: QIVc in Argentina would be cost-effective relative to QIVe. The potential health benefits and savings would be even higher in high egg-adaptation seasons.
Fisman D, Giglio N, Levin M, Nguyen V, Pelton S, Postma M Hum Vaccin Immunother. 2024; 20(1):2351675.
PMID: 38835218 PMC: 11155702. DOI: 10.1080/21645515.2024.2351675.
Fighting flu: novel CD8 T-cell targets are required for future influenza vaccines.
Leong S, Gras S, Grant E Clin Transl Immunology. 2024; 13(2):e1491.
PMID: 38362528 PMC: 10867544. DOI: 10.1002/cti2.1491.
Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Children: A Narrative Review.
Mould-Quevedo J, Pelton S, Nguyen V Vaccines (Basel). 2023; 11(10).
PMID: 37896996 PMC: 10610859. DOI: 10.3390/vaccines11101594.